Table 4.
Joint effect of preS2Δ38–55 and HBeAg seropositivity, viral load, HBsAg levels, HBV genotype, and AFB1 exposure, on HCC risk.
| Variables | Controls (n = 211) | HCC cases (n = 35) | OR (95% CI) | p value for heterogeneity |
|---|---|---|---|---|
| HBeAg/preS2Δ38–55 | 0.1 | |||
| (−)/(−) | 155 (74) | 12 (34) | 1.0 | |
| (−)/(+) | 38 (18) | 9 (26) | 3.1 (1.2–7.8) | |
| (+)/(−) | 15 (7) | 4 (11) | 3.4 (1.0–12.0) | |
| (+)/(+) | 3 (1) | 10 (29) | 43.1 (10.4–177.7) | |
| HBV DNA/preS2Δ38–55 | 0.1 | |||
| <2,000/(−) | 125 (59) | 8 (23) | 1.0 | |
| <2,000/(+) | 30 (14) | 3 (9) | 1.6 (0.4–6.2) | |
| ≥2,000/(−) | 45 (22) | 8 (23) | 2.8 (1.0–7.8) | |
| ≥2,000/(+) | 11 (5) | 16 (45) | 22.7 (8.0–64.9) | |
| HBsAg/preS2Δ38–55 | 0.6 | |||
| ≥10,000/(−) | 87 (51) | 4 (12) | 1.0 | |
| ≥10,000/(+) | 21 (12) | 5 (14) | 5.2 (1.3–21.0) | |
| <10,000/(−) | 46 (27) | 12 (34) | 5.7 (1.7–18.6) | |
| <10,000/(+) | 16 (10) | 14 (40) | 19.0 (5.5–65.3) | |
| Genotype/preS2Δ38–55 | <0.01 | |||
| E/(−) | 154 (73) | 7 (22) | 1.0 | |
| E/(+) | 34 (16) | 13 (41) | 8.4 (3.1–22.7) | |
| A/(−) | 16 (8) | 9 (28) | 12.4 (4.1–37.7) | |
| A/(+) | 7 (3) | 9 (9) | 9.4 (2.0–44.4) | |
| AFB1/preS2Δ38–55 | ||||
| (−)/(−) | 44 (59) | 2 (15) | 1.0 | 0.9 |
| (−)/(+) | 16 (22) | 4 (31) | 5.5 (0.9–33.0) | |
| (+)/(−) | 11 (15) | 3 (23) | 6.0 (0.9–40.4) | |
| (+)/(+) | 3 (4) | 4 (31) | 29.3 (3.7–230.4) |
AFB1, aflatoxin B1; OR, odds ratio.